{
  "ticker": "ARVN",
  "company_name": "Arvinas, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05654623",
      "title": "A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Advanced Breast Cancer",
      "start_date": "2023-03-03",
      "completion_date": "2028-05-15",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05501769",
      "title": "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Cancer",
      "start_date": "2022-09-08",
      "completion_date": "2025-08-25",
      "enrollment": 0,
      "sponsor": "Arvinas Estrogen Receptor, Inc."
    },
    {
      "nct_id": "NCT05463952",
      "title": "A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1",
      "condition": "Breast Neoplasms",
      "start_date": "2022-08-16",
      "completion_date": "2025-03-31",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT06911788",
      "title": "A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2025-04-03",
      "completion_date": "2025-06-13",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05732428",
      "title": "A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Breast Cancer",
      "start_date": "2023-02-20",
      "completion_date": "2024-11-01",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05930925",
      "title": "A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2023-06-12",
      "completion_date": "2023-08-14",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT06256510",
      "title": "A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2024-02-08",
      "completion_date": "2024-05-13",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05673889",
      "title": "A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2023-01-27",
      "completion_date": "2023-04-19",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT06125522",
      "title": "TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Breast Cancer",
      "start_date": "2024-01-10",
      "completion_date": "2026-04-30",
      "enrollment": 0,
      "sponsor": "Pfizer"
    },
    {
      "nct_id": "NCT05909397",
      "title": "A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Breast Cancer",
      "start_date": "2023-08-09",
      "completion_date": "2026-12-30",
      "enrollment": 0,
      "sponsor": "Pfizer"
    }
  ],
  "summary": {
    "total_trials": 26,
    "by_phase": {
      "PHASE3": 2,
      "PHASE1": 16,
      "PHASE1, PHASE2": 7,
      "PHASE2": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 8,
      "COMPLETED": 15,
      "RECRUITING": 2,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 10,
    "completed_trials": 15,
    "conditions": [
      "Advanced Breast Cancer",
      "Breast Cancer",
      "Breast Neoplasms",
      "Healthy",
      "Healthy Participants",
      "KRAS G12D Mutation, Advanced Solid Cancer",
      "Prostate Cancer Metastatic",
      "Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:19.745710",
    "search_query": "Arvinas, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Arvinas,+Inc."
  }
}